Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Drug attack shrink tough lung cancers?

NCT ID NCT06437509

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining an experimental drug called BL-B01D1 with a PD-1 monoclonal antibody can shrink tumors in people with extensive-stage small cell lung cancer. The study enrolls 66 adults aged 18 to 75 who have newly diagnosed, advanced disease. Researchers are measuring how many patients respond to the treatment and how long they live without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of an experimental drug called BL-B01D1 (izalontamab brengitecan) and a PD-1 monoclonal antibody
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced small cell lung cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is an early-phase trial with only 66 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai East Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.